Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

CLAIMS

1.(currently amended): A compound of ~~Formula (I) or a pharmaceutically acceptable salt thereof~~ the formula:



~~**Formula (I)**~~

or a pharmaceutically acceptable salt thereof.

2. (original): The compound of claim 1, wherein the pharmaceutically acceptable salt is a hydrochloride salt.

3. (currently amended): The compound of claim 1, wherein the pharmaceutically acceptable salt is the dihydrochloride salt. ~~of Formula (II).~~



~~Formula (II)~~

4. (currently amended): A pharmaceutical composition comprising an effective amount of the compound of claim 1 ~~Formula (I)~~ or a pharmaceutically acceptable salt thereof to treat a *Flaviviridae* infection, in a pharmaceutically acceptable carrier.



~~Formula (I)~~

5. (original): The pharmaceutical composition of claim 4 wherein the pharmaceutically acceptable salt is a hydrochloride salt.

6. (original): The pharmaceutical composition of claim 4 wherein the pharmaceutically acceptable salt is a dihydrochloride salt.

7. (currently amended): The pharmaceutical composition of ~~claim 4~~ claim 6, ~~whrein~~ wherein the pharmaceutically acceptable carrier is suitable for oral delivery.

8-12. (cancelled)

13. (currently amended): The pharmaceutical composition of ~~claim 4~~ claim 6, wherein the compound is in the form of a dosage unit.

14. (currently amended): The composition of claim 13, wherein the dosage unit contains ~~.01 to 50 mg~~ 50 mg to 1000 mg of the compound.

15. (original): The composition of claim 13, wherein said dosage unit is a tablet or capsule.

16. (currently amended): The composition of ~~claim 4~~ claim 6, wherein the compound is in substantially pure form.

17. (original): The compound of claims 1-3, wherein the compound is at least 90% by weight of the β-D-isomer.

18. (currently amended): The ~~compoound~~ compound of claims 1-3, wherein the compound is at least 95% by weight of the β-D-isomer.

19-36. (cancelled)

37. (currently amended): A compound of ~~Formula I or II~~ of the formula



~~wherein the 5'-hydroxyl group is replaced with a 5'-OR,~~ wherein R is mono, di or triphosphate; a stabilized phosphate prodrug; acyl; ~~alkyl;~~ sulfonate ester; ~~including alkyl or arylalkyl sulfonyl including methanesulfonyl and~~ or benzyl, wherein the phenyl group is optionally substituted; a lipid; an amino acid; a carbohydrate; a peptide; cholesterol; or other pharmaceutically acceptable leaving group which when administered *in vivo* is capable of providing a compound wherein R is independently H or phosphate.

38. (currently amended): A pharmaceutical composition that comprises the compound of ~~Formula I or II~~ claim 1, 2 or 3 in a pharmaceutically acceptable carrier, wherein the 5'-hydroxyl group is replaced with a 5'-OR, wherein R is mono, di or triphosphate; a stabilized phosphate prodrug; acyl; ~~alkyl;~~ sulfonate ester ~~including alkyl or arylalkyl sulfonyl including methanesulfonyl and;~~ or benzyl, wherein the phenyl group is optionally substituted; a lipid, an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered *in vivo* is capable of providing a compound wherein R is independently H or phosphate.

39-42. (cancelled).

43. (currently amended): The compound of claim 1, wherein the pharmaceutically acceptable salt is selected from tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, α-ketoglutarate, and α-glycerophosphate, formate, fumarate, propionate,

glycolate, lactate, pyruvate, oxalate, maleate, salicyate, sulfate, sulfonate, nitrate, ~~bicarbonate,~~ hydrobromate, hydrobromide, hydroiodide, ~~carbonate,~~ and phosphoric acid salts.

44. (currently amended): The composition of claim 4, wherein the pharmaceutically acceptable salt is selected from tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, α-ketoglutarate, and α-glycerophosphate, formate, fumarate, propionate, glycolate, lactate, pyruvate, oxalate, maleate, salicyate, sulfate, sulfonate, nitrate, ~~bicarbonate,~~ hydrobromate, hydrobromide, hydroiodide, ~~carbonate,~~ and phosphoric acid salts.

45. (cancelled).

46. (new): The composition of claim 13, wherein the dosage unit contains 70 mg to 1400 mg of the compound.

47. (new): The composition of claim 13, wherein the dosage unit contains 50 mg of the compound.

48. (new): The composition of claim 13, wherein the dosage unit contains 100 mg of the compound.

49. (new): The composition of claim 13, wherein the dosage unit contains 200 mg of the compound.

50. (new): The composition of claim 13, wherein the dosage unit contains 400 mg of the compound.

51. (new): The composition of claim 13, wherein the dosage unit contains 800 mg of the compound.

52. (new): The composition of claim 13, wherein the dosage unit contains 1000 mg of the compound.

53. (new): The pharmaceutical composition of claim 4, wherein the pharmaceutically acceptable carrier is suitable for oral delivery.

54. (new): The pharmaceutical composition of claim 4, wherein the compound is in the form of a dosage unit.

55. (new): The composition of claim 4, wherein the compound is in substantially pure form.

56. (new): The composition of claim 4, wherein the dosage unit contains 50 mg to 1000 mg of the compound.

57. (new): The composition of claim 4, wherein the dosage unit contains 70 mg to 1400 mg of the compound.

58. (new): The composition of claim 4, wherein the dosage unit contains 50 mg of the compound.

59. (new): The composition of claim 4, wherein the dosage unit contains 100 mg of the compound.

60. (new): The composition of claim 4, wherein the dosage unit contains 200 mg of the compound.

61. (new): The composition of claim 4, wherein the dosage unit contains 400 mg of the compound.

62. (new): The composition of claim 4, wherein the dosage unit contains 800 mg of the compound.

63. (new): The composition of claim 4, wherein the dosage unit contains 1000 mg of the compound.

64. (new): The pharmaceutical composition of claim 4, wherein the *Flaviviridae* infection is hepatitis C.

65. (new): The pharmaceutical composition of claim 5, wherein the *Flaviviridae* infection is hepatitis C.

66. (new): The pharmaceutical composition of claim 6, wherein the *Flaviviridae* infection is hepatitis C.

67. (new): The pharmaceutical composition of claim 7, wherein the *Flaviviridae* infection is hepatitis C.